Loading stock data…
CDXS
$2.67-0.15 (-5.32%)
Market ClosedLast close May 1
Codexis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Codexis, Inc. in the Healthcare sector is trading at $2.67. The stock is currently 31% below its 52-week high of $3.87, remaining 29.0% above its 200-day moving average. Technical signals show neutral RSI of 67 and bearish MACD signal, explaining why CDXS maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.67
Potential Upside
5%
Whystock Fair Value$2.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$6.58+146.6%
Range$2.00 – $11.00
Fundamentals
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$224.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.59%
Volume
Today's trading volume
843,697
Recent News
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
April 2026's Most Promising Penny Stocks
The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong financial foundations is crucial for investors seeking value beyond established names. Penny stocks, often representing smaller or newer companies, remain an intriguing investment area despite their somewhat outdated label; they can offer surprising...
Analyst Sentiment Unchanged After Codexis (CDXS) Earnings
Codexis, Inc. (NASDAQ:CDXS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 12, Matt Hewitt of Craig-Hallum reiterated his Buy rating on Codexis, Inc. (NASDAQ:CDXS). Just a day prior to this, TD Cowen analyst Brendan Smith also maintained his Hold rating on the stock with a price target of […]
Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance
In March 2026, Codexis reported that Q4 2025 revenue rose to US$38.92 million with net income of US$9.6 million, while full-year revenue reached US$70.39 million alongside a reduced net loss and new 2026 revenue guidance of US$72–76 million. The company also highlighted progress for its ECO Synthesis RNA manufacturing platform, including a new siRNA supply agreement for preclinical cardiovascular work and a major technology transfer deal with Merck that materially boosted results. With...
Codexis Inc (CDXS) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...
Codexis Inc (CDXS) reports a robust Q4 2025 with significant revenue growth, strategic CDMO agreements, and a strong cash position, despite ongoing challenges.